Tricking tumors into marking themselves for destruction with focused ultrasound
USC biomedical engineers have found a way to make a solid tumor paint a target on its own back in order to train the body’s immune system to find and destroy it.
Oncology & Cancer
Preoperative radiation may improve antitumor immune response in most common form of breast cancer
Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment respons…
Cell-free DNA could detect adverse events from immunotherapy
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns Hopkins Kimmel Cancer Center have found.
Off-the-shelf immunotherapy offers new hope for toughest myeloma
A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma—one of the most aggressive and treatment-resi…
New cancer therapy brings remission for patients with deadly T-cell leukemia
A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by an innovative form of immune therapy.
Next-generation CAR T cells show stronger, safer response in animal models
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, including those that typically es…
Real-time imaging captures what happens to cancer cells arriving in the brain
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is particularly severe and affect…
FDA approves expanded indication for Jaypirca
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly’s Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory chronic lymphocytic leukemi…
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment…
Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, accordin…